Deucravacitinib (SOTYKTU™) is a first-in-class, highly selective, oral tyrosine kinase 2
(TYK2) inhibitor. It acts via an allosteric mechanism, binding to the catalytically inactive …

Abstract The US Food and Drug Administration has approved a total of 37 new drugs in
2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 …

Purpose of the article Psoriasis is a chronic, immune-mediated, skin disease with a
significantly negative impact on patients' quality of life. Moderate-to-severe disease often …

Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory
condition, recognized under the term Psoriatic Disease (PsD). PsD has several …

The Janus kinases (JAKs) are key components of the JAK-STAT signaling pathway and are
involved in myriad physiological processes. Though they are the molecular targets of many …

Janus kinases (JAKs) are central components in cytokine signaling pathways. A number of
small molecule JAK inhibitors have been approved to treat a wide range of inflammatory and …

Objectives To evaluate the efficacy and safety of Janus kinase (JAK) inhibitors (Jakinibs) in
the treatment of psoriasis and psoriatic arthritis (PsA). Methods Databases including …

JAK kinase includes four family members: JAK1, JAK2, JAK3, and TYK2. It forms the JAK-
STAT pathway with signal transmitters and activators of subscription (STAT). This pathway is …

Plaque psoriasis is a common, long-lasting illness that affects the immune system and
causes significant negative impacts on a patient's physical health, well-being, and ability to …

Background Orally administered small-molecule drugs including tyrosine kinase 2 (TYK2)
inhibitors and phosphodiesterase 4 (PDE4) inhibitors are new candidates for systemic …